CAMBRIDGE, Mass., Sept. 24, 2009 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the results from the EMINENCE (Evaluation of M118 in Percutaneous Coronary Intervention) Phase 2 multicenter trial evaluating intravenous use of M118. The results were presented at the 21st Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, being held in San Francisco, CA. Sunil V. Rao, M.D., co-principal investigator for the trial, presented the results as a "First Report" during a session on novel antithrombotic agents. Dr. Rao is an Assistant Professor of Medicine at the Duke University Medical Center and Director of the Cardiac Catheterization Laboratories at the Durham, NC Veterans Affairs Medical Center.
